Clinical outcomes of patients stratified by WT1 and FLT3/ITD status
| . | WT1 wild-type . | WT1 mutant . | P . |
|---|---|---|---|
| CR rate at end of course 1 | |||
| FLT3/ITD neg, % | 81.5 | 82.2 | .932 |
| FLT3/ITD pos, % | 72.4 | 52.2 | .119 |
| P | .078 | .020 | |
| OS | |||
| FLT3/ITD neg, %, mean ± SD (n) | 56 ± 4 (696) | 56 ± 16 (45) | .8 |
| FLT3/ITD pos, %, mean ± SD (n) | 35 ± 13 (76) | 15 ± 15 (25) | .004 |
| P | .026 | .001 | |
| EFS | |||
| FLT3/ITD neg, %, mean ± SD (n) | 44 ± 4 (696) | 35 ± 16 (45) | .336 |
| FLT3/ITD pos, %, mean ± SD (n) | 24 ± 12 (76) | 15 ± 16 (25) | .036 |
| P | .017 | .019 | |
| RR | |||
| FLT3/ITD neg, %, mean ± SD (n) | 38 ± 5 (548) | 44 ± 18 (37) | .456 |
| FLT3/ITD pos, %, mean ± SD (n) | 61 ± 15 (55) | 70 ± 30 (12) | .403 |
| P | .005 | .115 | |
| FLT3/ITD, allelic ratio | .131 | ||
| Low, n (%) | 25 (33) | 4 (16) | |
| High, n (%) | 51 (67) | 21 (84) |
| . | WT1 wild-type . | WT1 mutant . | P . |
|---|---|---|---|
| CR rate at end of course 1 | |||
| FLT3/ITD neg, % | 81.5 | 82.2 | .932 |
| FLT3/ITD pos, % | 72.4 | 52.2 | .119 |
| P | .078 | .020 | |
| OS | |||
| FLT3/ITD neg, %, mean ± SD (n) | 56 ± 4 (696) | 56 ± 16 (45) | .8 |
| FLT3/ITD pos, %, mean ± SD (n) | 35 ± 13 (76) | 15 ± 15 (25) | .004 |
| P | .026 | .001 | |
| EFS | |||
| FLT3/ITD neg, %, mean ± SD (n) | 44 ± 4 (696) | 35 ± 16 (45) | .336 |
| FLT3/ITD pos, %, mean ± SD (n) | 24 ± 12 (76) | 15 ± 16 (25) | .036 |
| P | .017 | .019 | |
| RR | |||
| FLT3/ITD neg, %, mean ± SD (n) | 38 ± 5 (548) | 44 ± 18 (37) | .456 |
| FLT3/ITD pos, %, mean ± SD (n) | 61 ± 15 (55) | 70 ± 30 (12) | .403 |
| P | .005 | .115 | |
| FLT3/ITD, allelic ratio | .131 | ||
| Low, n (%) | 25 (33) | 4 (16) | |
| High, n (%) | 51 (67) | 21 (84) |